We thank Scialli for his interest in our study ([@b1-ehp0116-a0238b]). As he notes, we recognize that several factors could be responsible for the relationships observed between cord serum concentrations of perfluorooctane sulfonate/perfluorooctanoate (PFOS/PFOA) and birth weight, head circumference, and ponderal index in our study. Although diet may be a source of exposure (including consumption of polyfluoroalkyl compounds used in fast-food packaging), we are not aware of any evidence that such diets are associated with smaller size at birth. In fact, they may be related to obesity, which is associated with larger birth size ([@b4-ehp0116-a0238b]). Despite existing knowledge gaps on exposure pathways and the role of dietary intake, we do know that in our study, adjusting for body mass index of the mother had little impact on the associations observed.

Scialli posits that there may be a role of reduced plasma or body water volume on the associations observed. As we described in our article ([@b1-ehp0116-a0238b]), both preeclampsia and pregnancy-induced hypertension (PIH) are associated with poor maternal plasma volume expansion ([@b2-ehp0116-a0238b]), as is placental weight ([@b3-ehp0116-a0238b]). However, cord concentrations of PFOS and PFOA were not elevated among mothers with preeclampsia or PIH, and adjustment for these conditions did not appreciably alter the observed associations. Likewise, adjustment for placental weight, which may be associated with plasma volume of the infant, did not alter these associations. Despite theoretical considerations, we have not found support for this hypothesis. Further research is needed to better understand the pathways of human exposure and the role that pharmacokinetics of these compounds in the human body may play in the observed associations.
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